Earnings Feed
Start Free
Home/Filings/4/0001193125-26-016934
4//SEC Filing

Esposito Pamela 4

Accession 0001193125-26-016934

CIK 0001815442other
View on SEC.govCompany Profile

Filed

Jan 19, 7:00 PM ET

Accepted

Jan 20, 6:30 PM ET

Size

15.4 KB

Accession

0001193125-26-016934

Insider Transaction Report

Form 4
Period: 2026-01-20
Kymera Therapeutics, Inc.KYMR
Esposito Pamela
Director
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-01-20$31.20/sh+3,000$93,600→ 3,000 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-01-20$49.10/sh+2,500$122,750→ 5,500 total
  • Sale

    Common Stock

    [F1][F2]
    2026-01-20$66.68/sh−400$26,672→ 5,100 total
  • Sale

    Common Stock

    [F1][F3]
    2026-01-20$67.99/sh−4,900$333,145→ 200 total
  • Sale

    Common Stock

    [F1]
    2026-01-20$68.52/sh−200$13,704→ 0 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F4]
    2026-01-20−3,000→ 10,000 total
    Exercise: $31.20Exp: 2034-06-18→ Common Stock (3,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F4]
    2026-01-20−2,500→ 5,000 total
    Exercise: $49.10Exp: 2031-06-15→ Common Stock (2,500 underlying)
Footnotes (4)
  • [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.40 to $66.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.47 to $68.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F4]The shares underlying this stock option are fully vested and exercisable.
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact|2026-01-20

Documents

1 file

Issuer

Kymera Therapeutics, Inc.

CIK 0001815442

→
Entity typeother

Related Parties

1
  • filerCIK 0001744425

Filing Metadata

Form type
4
Filed
Jan 19, 7:00 PM ET
Accepted
Jan 20, 6:30 PM ET
Size
15.4 KB
View on SEC.gov